

## REFERENCES

- Abba, E., Shehu, Z., YORIYO, K. P., LAMAYI, D. W., AYUK, N. C., ABUBAKAR, Z. A., & KAMBEL, R. D. (2021). SYNTHESIS, CHARACTERIZATION AND APPLICATION OF CuO@ SiO<sub>2</sub> NANOCOMPOSITE USING GUM ARABIC: A BIO-FRIENDLY CONTROL MEASURE AGAINST LYMPHATIC FILARIASIS VECTOR. *PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY*, 99–108. <https://doi.org/10.48048/tis.2021.28>
- Abd El Hafiz Hassanain, N., Shaapan, M., Abd El Hafiz Hassanain, M., & Zaky, S. (2019). Comparison Between Insecticidal Activity of Lantana camara Extract and its Synthesized Nanoparticles Against Anopheline mosquitoes. *Pakistan Journal of Biological Sciences: PJBS*, 22(7), 327–334. <https://doi.org/10.3923/pjbs.2019.327.334>.
- Abdulwahab, Y., Ahmad, A., Wahid, I., & Taba, P. (2023). Green Synthesis of Copper Nanoparticles Using *Coffea arabica*: Larvicidal and Biochemical Study. *Journal of Bioscience and Applied Research*, 199–211.
- Abinaya, M., Vaseeharan, B., Rekha, R., Shanthini, S., Govindarajan, M., Alharbi, N. S., Kadaikunnan, S., Khaled, J. M., & Al-Anbr, M. N. (2019). Microbial exopolymer-capped selenium nanowires – Towards new antibacterial, antibiofilm and arbovirus vector larvicides? *Journal of Photochemistry and Photobiology B: Biology*, 192, 55–67. <https://doi.org/10.1016/j.jphotobiol.2019.01.009>
- Alemu, M. A., Birhanu Wubneh, Z., & Aduugna Ayanaw, M. (2022). Antidiarrheal Effect of 80% Methanol Extract and Fractions of the Roasted Seed of *Coffea arabica* Linn (Rubiaceae) in Swiss Albino Mice. *Evidence-Based Complementary and Alternative Medicine*, 2022, e9914936. <https://doi.org/10.1155/2022/9914936>
- Al-Ghabban, A., & Eldiasty, J. (2022). Green Synthesis of Copper Oxide Nanoparticle by Using *Achillea fragrantissima* and *Nigella sativa* Extracts and Their Effects as Larvicidal, Molluscicidal and Antimicrobial Agents. *Egyptian Academic Journal of Biological Sciences, E. Medical Entomology & Parasitology*, 14(2), 127–148. <https://doi.org/10.21608/eajbse.2022.270408>
- Al-Jubouri, A. K., Al-Saadi, N. H., & Kadhim, M. A. (2022). GREEN SYNTHESIS OF COPPER NANOPARTICLES FROM MYRTUS COMMUNIS LEAVES EXTRACT: CHARACTERIZATION, ANTIOXIDANT AND CATALYTIC ACTIVITY. *IRAQI JOURNAL OF AGRICULTURAL SCIENCES*, 53(2), 471–486. <https://doi.org/10.36103/ijas.v53i2.1555>
- Alnsour, L., Issa, R., Awwad, S., Albals, D., & Al-Momani, I. (2022). Quantification of total phenols and antioxidants in coffee samples of different origins and evaluation of the effect of degree of roasting on their levels. *Molecules*, 27(5), 1591.
- Amer, M., & Awwad, A. (2020). *Green synthesis of copper nanoparticles by Citrus limon fruits extract, characterization and antibacterial activity*. <https://doi.org/10.5281/zenodo.4017993>
- Amjad, R., Mubeen, B., Ali, S. S., Imam, S. S., Alshehri, S., Ghoneim, M. M., Alzarea, S. I., Rasool, R., Ullah, I., Nadeem, M. S., & Kazmi, I. (2021). Green synthesis and characterization of copper nanoparticles using

- fortunella margarita leaves. *Polymers*, 13(24).  
<https://doi.org/10.3390/polym13244364>
- Anandhi, S., Saminathan, V. R., Yasotha, P., Saravanan, P. T., & Rajanbabu, V. (2020). Nano-pesticides in pest management. *J. Entomol. Zool. Stud*, 8, 685–690.
- Aremu, H. K., Azeez, L. A., Adekale, I. A., Busari, H. K., Aremu-Adebayo, Z. A., Disu, A., Usman, H., Adeyemo, O., & Oyewole, O. (2022). *Green Synthesis of Silver Nanoparticles Using Azadirachta Indica and Their Biototoxicity Against Larvae of Culex Quinquefasciatus* (SSRN Scholarly Paper 4238690). <https://doi.org/10.2139/ssrn.4238690>
- Aziz, A. T. (2022). Toxicity of Ulva lactuca and green fabricated silver nanoparticles against mosquito vectors and their impact on the genomic DNA of the dengue vector *Aedes aegypti*. *IET Nanobiotechnology*, 16(4), 145–157. <https://doi.org/10.1049/nbt2.12082>
- Azmy, R. M., El Gohary, E. G. E., Salem, D. A., Abdou, M. A., Salama, M. S., & Mahmoud, D. M. (2021). Biochemical and histopathological effect of the essential oil of *Citrus sinensis* (L.) Osbeck on larvae of *Culex pipiens* Linnaeus, 1758 (Diptera: Culicidae). *Aquatic Insects*, 42(1), 78–90. <https://doi.org/10.1080/01650424.2020.1871025>
- Baz, M. M., El-Barkey, N. M., Kamel, A. S., El-Khawaga, A. H., & Nassar, M. Y. (2022). Efficacy of porous silica nanostructure as an insecticide against filarial vector *Culex pipiens* (Diptera: Culicidae). *International Journal of Tropical Insect Science*, 42(3), 2113–2125. <https://doi.org/10.1007/s42690-022-00732-7>
- Bukhari, S. I., Hamed, M. M., Al-Agamy, M. H., Gazwi, H. S. S., Radwan, H. H., & Youssif, A. M. (2021). Biosynthesis of Copper Oxide Nanoparticles Using *Streptomyces* MHM38 and Its Biological Applications. *Journal of Nanomaterials*, 2021, e6693302. <https://doi.org/10.1155/2021/6693302>
- Çelik, C., Büyükgüzel, K., & Büyükgüzel, E. (2019). The effects of oxyclozanide on survival, development and total protein of *Galleria mellonella* L. (Lepidoptera: Pyralidae). *Journal of the Entomological Research Society*, 21(1), 95–108.
- Chimkhan, N., Thammasittirong, S. N.-R., Roytrakul, S., Krobthong, S., & Thammasittirong, A. (2022). Proteomic Response of *Aedes aegypti* Larvae to Silver/Silver Chloride Nanoparticles Synthesized Using *Bacillus thuringiensis* subsp. *Israelensis* Metabolites. *Insects*, 13(7), Article 7. <https://doi.org/10.3390/insects13070641>
- Cho, A. R., Park, K. W., Kim, K. M., Kim, S. Y., & Han, J. (2014). Influence of Roasting Conditions on the Antioxidant Characteristics of Colombian Coffee (*Coffea arabica* L.) Beans. *Journal of Food Biochemistry*, 38(3), 271–280. <https://doi.org/10.1111/jfbc.12045>
- Chompunut, L., Wanaporn, T., Anupong, W., Narayanan, M., Alshiekheid, M., Sabour, A., Karuppusamy, I., Lan Chi, N. T., & Shanmuganathan, R. (2022). Synthesis of copper nanoparticles from the aqueous extract of *Cynodon dactylon* and evaluation of its antimicrobial and photocatalytic properties. *Food and Chemical Toxicology*, 166, 113245. <https://doi.org/10.1016/j.fct.2022.113245>
- Cimen, I. C. C., Danabas, D., & Ates, M. (2020). Comparative effects of Cu (60–80 nm) and CuO (40 nm) nanoparticles in *Artemia salina*: Accumulation,

- elimination and oxidative stress. *Science of The Total Environment*, 717, 137230. <https://doi.org/10.1016/j.scitotenv.2020.137230>
- Danbature, W. L., Shehu, Z., Mai, A. J., Magaji, B., Adam, M. M., & Bunu, M. A. (2020). Green synthesis, characterization and larvicidal activity of Cu/Ni bimetallic nanoparticles using fruit extract of Palmyra palm. *International Journal of Chemistry and Materials Research*, 8(1), 20–25. <https://doi.org/10.18488/journal.64.2020.81.20.25>
- Das, P. E., Abu-Yousef, I. A., Majdalawieh, A. F., Narasimhan, S., & Poltronieri, P. (2020). Green Synthesis of Encapsulated Copper Nanoparticles Using a Hydroalcoholic Extract of Moringa oleifera Leaves and Assessment of Their Antioxidant and Antimicrobial Activities. *Molecules*, 25(3), Article 3. <https://doi.org/10.3390/molecules25030555>
- Davarnejad, R., Azizi, A., Asadi, S., & Mohammadi, M. (2022). Green Synthesis of Copper Nanoparticles using Centaurea cyanus Plant Extract: A Cationic Dye Adsorption Application. *Iranian Journal of Chemistry and Chemical Engineering*, 41(1), 1–14. <https://doi.org/10.30492/ijcce.2020.120707.3944>
- Dhavan, P. P., & Jadhav, B. L. (2020). Eco-friendly approach to control dengue vector *Aedes aegypti* larvae with their enzyme modulation by *Lumnitzera racemosa* fabricated zinc oxide nanorods. *SN Applied Sciences*, 2(5), 843. <https://doi.org/10.1007/s42452-020-2636-0>
- Durairaj, B., Santhi, R., & Hemalatha, A. (2018). Isolation of chitosan from fish scales of *Catla catla* and synthesis, characterization and screening for larvicidal potential of chitosan-based silver nanoparticles. *Drug Invention Today*, 10(8), 1357–1362.
- Durairaj, B., Xavier, T., & Muthu, S. (2014). Research article fungal generated titanium dioxide nanoparticles: A potent mosquito (*Aedes aegypti*) larvicidal agent. *Sch. Acad. J. Biosci*, 2, 651–658.
- Durdu, S., Tosun, S., Yalcin, E., Cavusoglu, K., Altinkok, A., Sagcan, H., Yurtsever, I., & Usta, M. (2022). Characterization and investigation of properties of copper nanoparticle coated TiO<sub>2</sub> nanotube surfaces on Ti6Al4V alloy. *Materials Chemistry and Physics*, 126741. <https://doi.org/10.1016/j.matchemphys.2022.126741>
- E El Gohary, E. G., M Farag, S., A El-Sayed, A., R Khattab, R., & M Mahmoud, D. (2021). Insecticidal activity and biochemical study of the clove oil (*Syzygium aromaticum*) nano-formulation on *Culex pipiens* L. (Diptera: Culicidae). *Egyptian Journal of Aquatic Biology and Fisheries*, 25(1), 227–239. <https://doi.org/10.21608/EJABF.2021.137233>
- El-Saadony, M. T., Fouda, M. M. G., Ajarem, J., Maodaa, S. N., Abd El-Hack, M. E., Taha, A. E., Ajarem, J. S., Allam, A. A., & Elshaer, N. (2020). Ecofriendly synthesis and insecticidal application of copper nanoparticles against the storage pest *Tribolium castaneum*. *Nanomaterials*, 10, 587. <https://doi.org/10.3390/nano1003058>
- gomaa, alshimaa, saleh, rania, Elsayed, A., & daher, ahmed. (2021). Green Synthesis of copper Nanoparticles: Synthesis, Characterization and their application: About Future. *Egyptian Journal of Chemistry*, 0(0), 0–0. <https://doi.org/10.21608/ejchem.2021.87059.4209>
- Hajzadeh, Y. S., Harzandi, N., Babapour, E., Yazdani, M., & Ranjbar, R. (2022). Green Synthesis and Characterization of Copper Nanoparticles Using

- Iranian Propolis Extracts. *Advances in Materials Science and Engineering*, 2022, e8100440. <https://doi.org/10.1155/2022/8100440>
- Halawa, S. M. (2021). Efficacy of Chlorpyrifos and Bacillus Thuringiensis Israelensis against Culex Pipiens (L.). *Annals of Agricultural Science, Moshtohor*, 59(3), 577–584.
- Haridas, E. S., Bhattacharya, S., Varma, M. K., & Chandra, G. K. (2022). Green synthesis of eco-friendly silver nanoparticles using *Coffee arabica* leaf extract and development of a cost-effective biosensor for cysteine. *arXiv Preprint arXiv:2209.03823*. <https://doi.org/10.48550/arXiv.2209.03823>
- Hassan, S. E.-D., Fouda, A., Radwan, A. A., Salem, S. S., Barghoth, M. G., Awad, M. A., Abdo, A. M., & El-Gamal, M. S. (2019). Endophytic actinomycetes *Streptomyces* spp mediated biosynthesis of copper oxide nanoparticles as a promising tool for biotechnological applications. *JBIC Journal of Biological Inorganic Chemistry*, 24(3), 377–393. <https://doi.org/10.1007/s00775-019-01654-5>
- Herawati, D., Giriwono, P. E., Dewi, F. N. A., Kashiwagi, T., & Andarwulan, N. (2019). Critical roasting level determines bioactive content and antioxidant activity of Robusta coffee beans. *Food Science and Biotechnology*, 28(1), 7–14. <https://doi.org/10.1007/s10068-018-0442-x>
- Ikram, M., Javed, B., & Raja, N. I. (2021). Biomedical potential of plant-based selenium nanoparticles: A comprehensive review on therapeutic and mechanistic aspects. *International Journal of Nanomedicine*, 16, 249. <https://doi.org/10.2147/IJN.S295053>
- Ishaque, N. (2018). Biosynthesis, characterization and antibacterial activity of copper oxide nanoparticles (CuO NPs) from actinomycetes. *Biocatalysis and Agricultural Biotechnology*, 15, 56–62.
- Jampilek, J., Král'ová, K., & Fedor, P. (2020). Bioactivity of nanoformulated synthetic and natural insecticides and their impact on environment. *Nanopesticides: From Research and Development to Mechanisms of Action and Sustainable Use in Agriculture*, 165–225. [https://doi.org/10.1007/978-3-030-44873-8\\_7](https://doi.org/10.1007/978-3-030-44873-8_7)
- Jayadev, A., & Krishnan B, N. (2021). Green Synthesis of Copper Nanoparticles and its Characterization. *Journal of Scientific Research*, 65(01), 80–84. <https://doi.org/10.37398/JSR.2021.650111>
- Jung, S., Gu, S., Lee, S.-H., & Jeong, Y. (2021). Effect of roasting degree on the antioxidant properties of espresso and drip coffee extracted from *Coffea arabica* cv. Java. *Applied Sciences*, 11(15), 7025.
- Kamaraj, C., Ragavendran, C., Manimaran, K., Sarvesh, S., Islam, A. R. M. T., & Malafaia, G. (2023). Green synthesis of silver nanoparticles from *Cassia Auriculata*: Targeting antibacterial, antioxidant activity, and evaluation of their possible effects on saltwater microcrustacean, *Artemia Nauplii* (non-target organism). *Science of The Total Environment*, 861, 160575. <https://doi.org/10.1016/j.scitotenv.2022.160575>
- Kastamonuluoğlu, S., Büyükgüzel, K., & Büyükgüzel, E. (2020). The use of dietary antifungal agent terbinafine in artificial diet and its effects on some biological and biochemical parameters of the model organism *Galleria mellonella* (Lepidoptera: Pyralidae). *Journal of Economic Entomology*, 113(3), 1110–1117. <https://doi.org/10.1093/jeet/toaa039>

- Kh, S. D., & Keshan, B. (2019). Mobilization of fat body glycogen and haemolymph trehalose under nutritional stress in *Bombyx mori* larvae in relation to their physiological age and the duration of food deprivation. *Biologia*, 74(6), 649–660. <https://doi.org/10.2478/s11756-019-00196-0>
- Khan, N., Khan, I., Nadhman, A., Azam, S., Ullah, I., Ahmad, F., & Khan, H. A. (2020). *Pinus wallichiana*-synthesized silver nanoparticles as biomedical agents: In-vitro and in-vivo approach. *Green Chemistry Letters and Reviews*, 13(2), 69–82. <https://doi.org/10.1080/17518253.2020.1733105>
- Kumaresn, K., Parthiban, D., Sivanarayan, V., Arun, N., & Kumaravel, P. (2015). Toxicity Effect of Copper oxide Nanoparticles on *Artemia salina*. *Research Journal of Pharmacology and Pharmacodynamics*, 7(2), 53–60.
- Liu, X., Yan, J., Wu, X., Wu, X., Zhang, Y., & Li, B. (2022). Biosafety evaluation of  $\text{Li}_{2\text{SiO}_5}$  whisker-reinforced glass-ceramics. *Biomedical Materials*, 17(2), 025011. <https://doi.org/10.1088/1748-605X/ac4e65>
- Madasamy, M., Sahayaraj, K., Sayed, S. M., Al-Shuraym, L. A., Selvaraj, P., El-Arnaouty, S.-A., & Madasamy, K. (2023). Insecticidal Mechanism of Botanical Crude Extracts and Their Silver Nanoliquids on *Phenacoccus solenopsis*. *Toxics*, 11(4), Article 4. <https://doi.org/10.3390/toxics11040305>
- Mahmoud, D. M., Abd El-Bar, M. M., Salem, D. A., & Rady, M. H. (2019). Larvicidal potential and ultra-structural changes induced after treatment of *Culex pipiens* L.(Diptera: Culicidae) larvae with some botanical extracted oils. *Synthesis*, 12, 15–18.
- Marzban, A., Mirzaei, S. Z., Karkhane, M., Ghotekar, S. K., & Danesh, A. (2022). Biogenesis of copper nanoparticles assisted with seaweed polysaccharide with antibacterial and antibiofilm properties against methicillin-resistant *Staphylococcus aureus*. *Journal of Drug Delivery Science and Technology*, 74, 103499. <https://doi.org/10.1016/j.jddst.2022.103499>
- Muthamil Selvan, S., Vijai Anand, K., Govindaraju, K., Tamilselvan, S., Kumar, V. G., Subramanian, K. S., Kannan, M., & Raja, K. (2018). Green synthesis of copper oxide nanoparticles and mosquito larvicidal activity against dengue, zika and chikungunya causing vector *Aedes aegypti*. *IET Nanobiotechnology*, 12(8), 1042–1046. <https://doi.org/10.1049/iet-nbt.2018.5083>
- Nzube, O. B., & Ukoha, U. (2022). PHYTOCHEMICAL STUDIES ON GREEN COFFEE BEAN (*COFFEE ARABICA*). *Certified Journal | Obinwa et al. World Journal of Pharmaceutical Research*, 11(1), 1656. <https://doi.org/10.20959/wjpr20221-22604>
- Parthiban, E., Arokiyaraj, C., & Ramanibai, R. (2020). *Annona muricata*: An alternate mosquito control agent with special reference to inhibition of detoxifying enzymes in *Aedes aegypti*. *Ecotoxicology and Environmental Safety*, 189, 110050. <https://doi.org/10.1016/j.ecoenv.2019.110050>
- Pecoraro, R., Scalisi, E. M., Messina, G., Fragalà, G., Ignoto, S., Salvaggio, A., Zimbone, M., Impellizzeri, G., & Brundo, M. V. (2021). *Artemia salina*: A microcrustacean to assess engineered nanoparticles toxicity. *Microscopy Research and Technique*, 84(3), 531–536. <https://doi.org/10.1002/jemt.23609>

- Phang, Y.-K., Aminuzzaman, M., Akhtaruzzaman, M., Muhammad, G., Ogawa, S., Watanabe, A., & Tey, L.-H. (2021). Green synthesis and characterization of CuO nanoparticles derived from papaya peel extract for the photocatalytic degradation of palm oil mill effluent (POME). *Sustainability*, *13*(2), 796. <https://doi.org/10.3390/su13020796>
- Pourahmad, J., Salami, M., & Zarei, M. H. (2022). Comparative Toxic Effect of Bulk Copper Oxide (CuO) and CuO Nanoparticles on Human Red Blood Cells. *Biological Trace Element Research*. <https://doi.org/10.1007/s12011-022-03149-y>
- Ragavendran, C., Kamaraj, C., Jothimani, K., Priyadharsan, A., Anand Kumar, D., Natarajan, D., & Malafaia, G. (2023). Eco-friendly approach for ZnO nanoparticles synthesis and evaluation of its possible antimicrobial, larvicidal and photocatalytic applications. *Sustainable Materials and Technologies*, *36*, e00597. <https://doi.org/10.1016/j.susmat.2023.e00597>
- Raguvaran, K., Kalpana, M., Manimegalai, T., Kalaivani, S., Devapriya, P., Siddharthan, N., Balakrishnan, R., Silambarasan, T. S., & Maheswaran, R. (2022). Larvicidal, antioxidant and biotoxicity assessment of (2-(((2-ethyl-2 methylhexyl) oxy) carbonyl) benzoic acid isolated from *Bacillus pumilus* against *Aedes aegypti*, *Anopheles stephensi* and *Culex quinquefasciatus*. *Archives of Microbiology*, *204*(10), 650.
- Rajagopal, G., Nivetha, A., Sundar, M., Panneerselvam, T., Murugesan, S., Parasuraman, P., Kumar, S., Ilango, S., & Kunjiappan, S. (2021). Mixed phytochemicals mediated synthesis of copper nanoparticles for anticancer and larvicidal applications. *Heliyon*, *7*(6), e07360. <https://doi.org/10.1016/j.heliyon.2021.e07360>
- Said, R., Hasieb, H., Moustafa, M., Salah, M., Soliman, Kloas, W., & Osman, A. (2019). Haematological, Serological and Genotoxic Findings in the African Catfish *Clarias gariepinus* after the Administration of Copper Nanoparticles and Penconazole. *EC Veterinary Science*, *4*(10), 1–14.
- Sandhu, K. K., Vashishat, N., & Kocher, D. K. (2023). Formulation of eucalyptus oil-zinc sulphide hybrid nanoemulsion and evaluation of its larvicidal potential against *Aedes aegypti*. *African Entomology*, *31*, 1–8. <https://doi.org/10.17159/2254-8854/2023/a12791>
- Sandhu, K. K., Vashishat, N., & Sidhu, A. (2022). Larvicidal potential of copper sulphide nano aqua dispersions against *Aedes aegypti* (Linnaeus). *African Entomology*, *30*, 1–5. <https://doi.org/10.17159/2254-8854/2022/a13589>
- Sharawi, S. (2023). The toxic effect of some traditional herbs in the Kingdom of Saudi Arabia against *Aedes aegypti* larvae as a safety method for control. *International Journal of Mosquito Research*, *10*, 15–20. <https://doi.org/10.22271/23487941.2023.v10.i1a.657>
- Sharon, E. A., Velayutham, K., & Ramanibai, R. (2018). Biosynthesis of Copper Nanoparticles using *Artocarpus heterophyllus* against Dengue Vector *Aedes aegypti*. *International Journal of Life-Sciences Scientific Research*, *4*(4), 1872–1879. <https://doi.org/10.21276/ijlssr.2018.4.4.4>
- Shehu, Z., Danbature, W., Abba, E., Nsor, C., & Yoriyo, K. (2021). SYNTHESIS, CHARACTERIZATION AND APPLICATION OF CuO@SiO<sub>2</sub> NANOCOMPOSITE USING GUM ARABIC: A BIO-FRIENDLY CONTROL MEASURE AGAINST LYMPHATIC FILARIASIS VECTOR. *Plant Cell*


- Biotechnology and Molecular Biology*, 22, 99–108. <https://www.researchgate.net/publication/353224321>
- Shehu, Z., Danbature, W. L., Magaji, B., Adam, M. M., Bunu, M. A., Mai, A. J., & Mela, Y. (2020). Green synthesis and nanotoxicity assay of Copper-Cobalt bimetallic nanoparticles as a novel nanolarvicide for mosquito larvae management. *The International Journal of Biotechnology*, 9(2), 99–104. <https://doi.org/10.18488/journal.57.2020.92.99.104>
- Sitepu, F. Y., & Aditama, W. (2019). The effectiveness of arabica coffee (*Coffea arabica* L) grounds on mortality and growth of *Aedes aegypti* Larva. *International Journal of Mosquito Research*, 6(1), 34–37.
- Soliman, A., Nada, M., & Gad, A. (2022). Evaluation the Effects of the Entomopathogenic Fungus *Beauveria Bassiana* (Ascomycota: Hypocrales) on some Histological and Physiological Parameters for the Green Bug *Nezara Viridula* (L.)(Hemiptera: Pentatomidae). *Alexandria Science Exchange Journal*, 43(2), 229–238. <https://doi.org/DOI:10.21608/asejaiqjsae.2022.239209>
- Sugeçti, S., & Büyükgüznel, K. (2018). Effects of Oxfendazole on Metabolic Enzymes in Hemolymph of *Galleria mellonella* L.(Lepidoptera: Pyralidae) Larvae Reared on Artificial Diet. *Karaelmas Science & Engineering Journal*, 8(2).
- Sugeçti, S., & BÜYÜKGÜZEL, K. (2022). Effects of Ni (II) p-hydroxybenzoate with caffeine on metabolic, antioxidant, and biochemical parameters of model insect *Galleria mellonella* L.(Lepidoptera: Pyralidae). *Turkish Journal of Zoology*, 46(1), 167–174. <https://DOI10.3906/zoo-2110-6>
- Sugeçti, S., Tunçsoy, B., Büyükgüznel, E., Özalp, P., & Büyükgüznel, K. (2021). Ecotoxicological effects of dietary titanium dioxide nanoparticles on metabolic and biochemical parameters of model organism *Galleria mellonella* (Lepidoptera: Pyralidae). *Journal of Environmental Science and Health, Part C*, 39(4), 423–434. <https://doi.org/10.1080/26896583.2021.1969846>
- Sukumar, S., Rudrasenan, A., & Padmanabhan Nambiar, D. (2020). Green-Synthesized Rice-Shaped Copper Oxide Nanoparticles Using *Caesalpinia bonducella* Seed Extract and Their Applications. *ACS Omega*, 5(2), 1040–1051. <https://doi.org/10.1021/acsomega.9b02857>
- Sultana, N., K. Raul, P., Goswami, D., Das, D., Islam, S., Tyagi, V., Das, B., K. Gogoi, H., Chattopadhyay, P., & S. Raju, P. (2020). Bio-nanoparticle assembly: A potent on-site biolarvicidal agent against mosquito vectors. *RSC Advances*, 10(16), 9356–9368. <https://doi.org/10.1039/C9RA09972G>
- Tahir, A., Quispe, C., Herrera-Bravo, J., Iqbal, H., ul Haq, Z., Anum, F., Javed, Z., Sehar, A., & Sharifi-Rad, J. (2022). Green synthesis, characterization and antibacterial, antifungal, larvicidal and anti-termite activities of copper nanoparticles derived from *Grewia asiatica* L. *Bulletin of the National Research Centre*, 46(1), 188. <https://doi.org/10.1186/s42269-022-00877-y>
- Tangtrakulwanich, K., Suwannawong, B., & Nakrung, P. (2022). The Comparative Study of Arabica Used Coffee Grounds and Temephos in Controlling the *Aedes aegypti* Larvae. *Journal of Food Science and Agricultural Technology (JFAT)*, 6(1), Article 1.
- Thanasoponkul, W., Changbunjong, T., Sukkurd, R., & Saiwichai, T. (2023). Spent Coffee Grounds and Novaluron Are Toxic to *Aedes aegypti* (Diptera: Culicidae) Larvae. *Insects*, 14(6), 564.

- Tunçsoy, B., Sugeçti, S., Büyükgüzel, E., Özalp, P., & Büyükgüzel, K. (2021). Effects of copper oxide nanoparticles on immune and metabolic parameters of *Galleria mellonella* L. *Bulletin of Environmental Contamination and Toxicology*, *107*(3), 412–420. <https://doi.org/10.1007/s00128-021-03261-0>
- Turakhia, B., Divakara, M. B., Santosh, M. S., & Shah, S. (2020). Green synthesis of copper oxide nanoparticles: A promising approach in the development of antibacterial textiles. *Journal of Coatings Technology and Research*, *17*(2), 531–540. <https://doi.org/10.1007/s11998-019-00303-5>
- Vanitha, G. (2021). Eco-Friendly Synthesis of some Novel Metal Nanoparticles Mediated by *Ocimum Basilicum*-Lamiaceae (Thiru Neetru Pathilai) Leaves Extract. *International Journal for Research in Applied Science and Engineering Technology*, *9*(1), 548–561. <https://doi.org/10.22214/ijraset.2021.32881>
- Vivekanandhan, P., Swathy, K., Thomas, A., Kweka, E. J., Rahman, A., Pittarate, S., & Krutmuang, P. (2021). Insecticidal efficacy of microbial-mediated synthesized copper nano-pesticide against insect pests and non-target organisms. *International Journal of Environmental Research and Public Health*, *18*(19). <https://doi.org/10.3390/ijerph181910536>





## APPENDIXES

## Appendix 1. Abstract Research




## Appendix 2. U V Spectrophotometer CuNPs Synthesis Ratio (1:1)



### Appendix 3. UV Spectrophotometer CuNPs Synthesis Ratio (2:1)

Data Set: 2-1.spc - RawData

(2:1) 3 days




[Measurement Properties]  
 Wavelength Range (nm.): 200.00 to 800.00  
 Scan Speed: Medium  
 Sampling Interval: 0.5  
 Auto Sampling Interval: Enabled  
 Scan Mode: Single

No.	P/V	Wavelength	Abs.	Description
1	⊕	348.00	0.274	
2	⊕	264.50	0.678	

Data Set: 2-1a.spc - RawData

(2:1) 30 days




[Measurement Properties]  
 Wavelength Range (nm.): 200.00 to 800.00  
 Scan Speed: Medium  
 Sampling Interval: 0.5  
 Auto Sampling Interval: Enabled  
 Scan Mode: Single

No.	P/V	Wavelength	Abs.	Description
1	⊕	262.50	0.907	
2	⊕	257.00	0.906	

## Appendix 4. U V Spectrophotometer CuNPs Synthesis Ratio (10:1)

Data Set: 10-1.spc - RawData

(10:1) 3 days




[Measurement Properties]  
Wavelength Range (nm.):  
Scan Speed:  
Sampling Interval:  
Auto Sampling Interval:  
Scan Mode:

200.00 to 800.00  
Medium  
0.5  
Enabled  
Single

No.	P/V	Wavelength	Abs.	Description
1	●	677.00	0.009	
2	●	347.50	0.048	
3	●	264.00	0.142	

Data Set: 10-1a.spc - RawData

(10:1) 30 days



[Measurement Properties]  
Wavelength Range (nm.):  
Scan Speed:  
Sampling Interval:  
Auto Sampling Interval:  
Scan Mode:

200.00 to 800.00  
Medium  
0.5  
Enabled  
Single

No.	P/V	Wavelength	Abs.	Description
1	●	262.50	0.215	
2	●	256.50	0.226	
3	●	250.50	0.225	

## Appendix 5. Data XRD

```

*** Basic Data Process ***
Group      : Standard
Data       : yousefAhmad


# Strongest 3 peaks
no. peak  2Theta      d          I/I1      FWHM      Intensity  Integrated Int
no.       (deg)         (Å)        (deg)     (deg)     (Counts)  (Counts)
1 10      21.3900      4.15075    100      1.10000    24      1372
2 17      28.0700      3.17630    88       0.52000    21      602
3 19      31.2500      2.85995    79       0.70000    19      781

# Peak Data List
peak      2Theta      d          I/I1      FWHM      Intensity  Integrated Int
no.       (deg)         (Å)        (deg)     (deg)     (Counts)  (Counts)
1 10.7200  8.24615    17      0.12000    4      43
2 11.7800  7.50641    13      0.04000    3      21
3 12.9400  6.83599    8       0.04000    2      4
4 14.5283  6.09203    21     0.04330    5      24
5 15.3550  5.76585    46     0.57000    11     579
6 16.6400  5.32337    25     0.00000    6      0
7 17.4100  5.08963    46     0.58000    11     567
8 18.5400  4.78189    29     0.08000    7      64
9 19.1800  4.62374    46     0.56000    11     582
10 21.3900  4.15075    100     1.10000    24     1372
11 22.0600  4.02618    46     0.60000    11     347
12 22.9633  3.86980    29     0.39330    7      191
13 24.0360  3.69947    75     0.55200    18     501
14 24.9700  3.56317    13     0.10000    3      47
15 25.6000  3.47689    21     0.08000    5      49
16 26.5600  3.35336    29     0.12000    7      133
17 28.0700  3.17630    88     0.52000    21     602
18 29.3500  3.04063    54     0.74000    13     709
19 31.2500  2.85995    79     0.70000    19     781
20 32.5816  2.74604    38     0.34330    9      165
21 33.5800  2.66665    4       0.00000    1      0
22 35.7100  2.51232    33     0.38000    8      137
23 36.5600  2.45584    4       0.00000    1      0
24 37.7300  2.38233    42     0.42000    10     243
25 39.0100  2.30705    8       0.10000    2      23
26 39.9300  2.25599    17     0.14000    4      58
27 40.9000  2.20470    29     0.08000    7      89
28 42.3850  2.13083    46     0.37000    11     256
29 44.0000  2.05629    50     0.52000    12     389
30 45.2150  2.00382    21     0.05000    5      38
31 46.4400  1.95377    38     0.44000    9      261
32 47.9300  1.89646    33     0.54000    8      254
33 49.0400  1.85610    13     0.04000    3      17
34 49.9900  1.82303    21     0.06000    5      42
35 51.1300  1.78502    50     0.42000    12     363
36 52.5300  1.74070    17     0.30000    4      95
37 53.6000  1.70845    17     0.16000    4      57
38 54.6300  1.67864    29     0.14000    7      103
39 55.5800  1.65218    4       0.00000    1      0
40 56.8500  1.61825    21     0.10000    5      49
41 57.7300  1.59566    8       0.14000    2      21
42 59.2000  1.55950    13     0.04000    3      26
43 60.2400  1.53503    13     0.16000    3      41
44 61.1000  1.51547    13     0.04000    3      22
45 61.8200  1.49954    4       0.00000    1      0
46 62.6000  1.48272    25     0.16000    6      83
47 63.4800  1.46427    4       0.00000    1      0
48 64.2850  1.44786    50     0.43000    12     264

peak      2Theta      d          I/I1      FWHM      Intensity  Integrated Int
no.       (deg)         (Å)        (deg)     (deg)     (Counts)  (Counts)
50 66.6100  1.40285    25     0.26000    6      142
51 67.6200  1.38433    29     0.28000    7      209
52 68.4600  1.36938    21     0.20000    5      103
53 69.1300  1.35774    17     0.26000    4      90
54 69.8900  1.34482    17     0.22000    4      130
55 71.4400  1.31940    25     0.40000    6      165
56 73.3600  1.28954    17     0.20000    4      90
57 74.0250  1.27959    13     0.03000    3      16
58 75.4900  1.25836    13     0.10000    3      38
59 77.5350  1.23019    58     0.49000    14     346


```

## Appendix 6. The curves XRD



Appendix 7. Data FTIR *Coffee arabica*

SHIMADZU




	Peak	Intensity	Corr. Intensity	Base (H)	Base (L)	Area	Corr. Area
1	372.26	72.975	26.49	486.06	343.33	10.846	10.603
2	557.43	94.343	2.055	588.29	487.99	1.827	0.653
3	605.65	94.756	1.415	650.01	590.22	0.902	0.196
4	669.3	98.868	0.953	692.44	650.01	0.118	0.086
5	717.52	96.129	3.841	748.38	692.44	0.43	0.425
6	767.67	98.244	1.741	794.67	748.38	0.19	0.183
7	813.96	94.214	5.714	835.18	794.67	0.53	0.518
8	869.9	95.931	3.806	910.4	835.18	0.659	0.565
9	941.26	99.442	0.482	964.41	921.97	0.063	0.045
10	1026.13	88.068	7.86	1080.14	966.34	4.279	2.316
11	1087.85	92.443	0.935	1130.29	1082.07	1.083	0.208
12	1163.08	89.405	10.286	1203.58	1132.21	1.842	1.753
13	1246.02	96.288	3.599	1300.02	1215.15	0.833	0.795
14	1311.59	99.465	0.484	1328.95	1300.02	0.036	0.031
15	1379.1	93.697	6.061	1406.11	1342.46	0.865	0.798
16	1480.11	89.461	10.565	1485.19	1427.32	1.381	1.386
17	1519.91	97.905	1.898	1562.34	1498.69	0.341	0.292
18	1641.42	81.076	18.73	1718.58	1562.34	6.83	6.699
19	1745.58	74.434	25.402	1772.58	1720.5	2.978	2.94
20	1867.09	99.251	0.135	1870.95	1845.88	0.045	0.004
21	2135.2	99.012	0.094	2250.93	2123.63	0.332	0.054
22	2316.51	98.738	1.081	2339.65	2250.93	0.195	0.145
23	2684.91	99.491	0.057	2706.13	2673.34	0.067	0.004
24	2854.65	71.034	16.788	2877.79	2756.28	4.998	1.885
25	2924.09	56.088	35.012	2989.66	2879.72	12.425	8.506
26	3008.95	97.492	2.488	3030.17	2991.59	0.209	0.203
27	3446.79	48.329	51.497	3716.83	3030.17	113.206	112.688

Comment:  
Coffee Arabica

Date/Time: 9/13/2022 8:44:01 AM  
No. of Scans:  
Resolution:  
Apodization:

## Appendix 8. Data FTIR CuNPs

SHIMADZU



	Peak	Intensity	Corr. Intensity	Base (H)	Base (L)	Area	Corr. Area
1	372.26	73.523	26.261	482.2	343.33	10.946	10.688
2	617.22	68.491	31.362	684.73	484.13	14.357	14.01
3	758.02	91.507	8.652	786.96	686.66	1.41	1.504
4	815.89	95.761	4.034	839.03	788.89	0.504	0.466
5	866.04	98.937	1.013	898.83	846.75	0.16	0.147
6	927.76	97.896	2.123	943.19	898.83	0.176	0.175
7	979.84	94.235	5.705	997.2	943.19	0.566	0.56
8	1097.5	27.23	29.739	1126.43	999.13	37.419	15.229
9	1145.72	36.627	17.947	1222.87	1128.36	16.857	2.965
10	1247.94	95.083	1.894	1261.45	1222.87	0.579	0.178
11	1284.59	94.247	2.979	1315.45	1261.45	0.927	0.336
12	1388.75	77.44	9.194	1423.47	1317.38	6.994	2.094
13	1446.61	78.894	7.836	1489.05	1425.4	4.576	1.42
14	1517.98	93.79	5.804	1541.12	1494.83	0.654	0.572
15	1649.14	42.508	21.883	1687.71	1541.12	34.14	13.388
16	1708.93	49.383	9.645	1816.94	1689.64	21.284	3.79
17	1847.81	99.825	0.217	1857.45	1834.3	0.002	0.007
18	1921.1	98.606	1.298	1969.32	1872.88	0.292	0.251
19	2061.9	98.877	0.861	2098.55	2031.04	0.183	0.107
20	2119.77	99.539	0.16	2135.2	2098.55	0.059	0.013
21	2322.29	97.215	0.549	2337.72	2187.28	0.832	-0.071
22	2353.16	96.448	0.958	2368.59	2337.72	0.416	0.064
23	2511.32	99.491	0.219	2569.18	2438.02	0.222	0.058
24	2704.2	96.539	3.23	2746.63	2611.62	0.993	0.833
25	2781.35	99.009	0.664	2804.5	2746.63	0.132	0.056
26	2854.65	90.724	4.517	2873.94	2804.5	1.34	0.411
27	2926.01	81.097	15.096	2997.38	2875.86	4.964	3.167
28	3381.21	29.878	70.059	3701.4	2999.31	214.261	214.053
29	3730.33	96.336	3.608	3755.4	3701.4	0.392	0.379

Comment;  
AgNPs


Date/Time; 8/31/2022 2:38:41 PM  
No. of Scans;  
Resolution;  
Apodization;



## Appendix 9. CuNPs synthesis



Appendix 10. Treated *Aedes aegypti*



## Appendix 11 protocol DNA extraction

### DNA EXTRACTION

Isolate the genomic DNA of an adult mosquito (whole body) using a modified phenol-chloroform protocol

#### **Reagents and materials needed:**

Phenol/chloroform isoamyl alcohol (24:24:1)	
1X PBS Buffer	
ATL Buffer (from Dneasy kit)	
Absolute ethanol (ice-cold)	1.5 mL sterile tubes
70% ethanol	Tube rack
Proteinase K	Pipet tips and tip boxes
Chloroform	Plastic pestles
TE Buffer (pH 7.5 - 8)	Kim wipes
3M sodium acetate (pH 5.2)	Liquid waste container
RnaseA (100mg/mL)	

#### **Equipment needed:**

Centrifuge	Vortex mixer	Water bath	Autoclave
Fume hood	Freezer	Micro-Pipettes	

|

#### **Sample to be extracted:**

Larvae mosquitos

Initial preparation:

1. Wear lab gown, masker, gloves and foot protection shoes for your safety.
2. Disinfect the hood and work table with 70% ethanol.
3. Disinfect with 70% ethanol all the laboratory materials needed and then expose all in the hood under the UV lamp for 15 minutes before and after using.
4. All tubes, pipette tips, and plastic pestles that will be used should had been be sterilized (autoclaved).

Procedures:

1. Add 200  $\mu$ L 1X PBS into a 1.5 mL sterile tube and individual mosquito sample, then homogenized.

2. Digest 200  $\mu\text{L}$  PBS-homogenized samples in 180  $\mu\text{L}$  Buffer ATL\* and 20  $\mu\text{L}$  Proteinase K.
3. Incubate at 56°C overnight. Allow to cool down for 10 minutes.
4. Add 4  $\mu\text{L}$  RNaseA (100mg/mL). Vortex to mix.
5. Incubate at 37°C for 1 hour.
6. Add an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1). → *“equal” means equal volume to the volume of 200  $\mu\text{L}$  (1X PBS) + 180  $\mu\text{L}$  (Buffer ATL\*) + 20  $\mu\text{L}$  (Proteinase K) → 400  $\mu\text{L}$*
7. Vortex vigorously for 20 sec.
8. Centrifuge at 12, 000 RPM for 10 min.
9. Add 100  $\mu\text{L}$  of chloroform. Vortex vigorously for 20 sec.
10. Centrifuge at 12, 000 RPM for 2 min. Carefully transfer aqueous phase to new tube.
11. Add 1/10 volume of 3M sodium acetate, pH 5.2. Gently invert 10x. → *1/10 of aqueous phase (upper layer) collected in the previous step (10), see the volume in the pipet tip.*
12. Add 2 volumes (calculated after salt addition) of ice-cold 100% ethanol. Gently invert 10x. → *(For Eg.: upper layer is 200 $\mu\text{L}$  + 1/10 of 200 is 20 $\mu\text{L}$  so the ice-cold 100% ethanol to be added is [200 + 20]  $\mu\text{L}$  x 2 = 440 $\mu\text{L}$ )*
13. Incubate in -20°C for 1 hour to overnight.
14. Centrifuge at 12,000 RPM for 15 min. Carefully decant supernatant.
15. Wash pellet with 1 mL 70% ethanol (RT). Vortex briefly for 5 sec.
16. Centrifuge at 12,000 RPM for 2 min. Carefully decant supernatant.
17. Air dry for 15 min or until excess ethanol is evaporated.
18. Resuspend pellet in 30  $\mu\text{L}$  TE buffer (pH 8) or nuclease-free water.
19. Incubate in water bath for 10 min at 55°C. Briefly centrifuge to collect sample.

## Appendix 12. Total protein

### Total Protein Kit CliniQuant - FSR Biuret Method, End Point



For in vitro diagnostic use  
Read this pack insert thoroughly before use

REF	Pack Size	R1 Total Protein Reagent	R2 Total Protein Standard
TPRFSR-01	4 x 50ml	4 x 50ml	1 x 5ml
TPRFSR-02	2 x 500ml	2 x 500ml	2 x 5ml

#### INTENDED USE


This reagent is intended for quantitative determination of proteins concentration in human serum or plasma.

#### CLINICAL SIGNIFICANCE

Serum Total Protein is useful in monitoring change in the protein levels due to diseases. Increased levels are found in dehydration due to inadequate water intake or to excessive water loss as in severe vomiting, diarrhoea, Addison's disease and in multiple myeloma.

#### PRINCIPLE OF THE METHOD

Proteins peptidic bonds react with Cu(II) in alkaline solution to form blue-purple complex, the absorbance of which is measured at 546 nm. Each Cu(II) can complex up to 6 peptidic bonds.



#### KIT COMPONENTS

##### Composition

R1 - Total Protein Reagent : Cupric Sulphate 12.01 mmol/l, Potassium sodium tartarate 31.8 g/l, Potassium Iodide 54.21 mmol/l, Sodium Hydroxide 200 mmol/l

R2 - Total Protein Standard : 6.0 g/dl, BSA 60g/l, Sodium Azide 0.1%

#### MATERIALS REQUIRED BUT NOT PROVIDED

Laboratory instrumentation, Spectrophotometer UV/VIS with thermostatic cuvette holder or clinical chemistry analyzer: semi automated, calibrated micropipettes, glass or high quality polystyrene cuvettes, test tube/ rack, heating bath, controls, saline.

#### REAGENT PREPARATION, STORAGE & STABILITY

Reagent is ready to use. Keep away from direct light sources.

Stability: up to expiration date on labels at 2-8 °C.

Upon opening of kit, store Reagent R1 at 15 -30 °C and standard at 2-8 °C.

Stability since first opening of reagent bottle: preferable within 60 days at 15 -30 °C.

#### REAGENT DETERIORATION

1. Discard the reagent if absorbance exceeds 0.2 at 546 nm against distilled water.
2. Keep the Standard vial plugged after use, in order to avoid deterioration.

#### WARNINGS AND PRECAUTIONS

1. Reagent contains strong alkali. Do not mouth pipette. It is suggested to handle carefully, avoiding contact with skin and ingestion.
2. Specimens should be considered infectious and handled appropriately.
3. Perform the test according to the general "Good Laboratory Practice" (GLP) guidelines.

#### SPECIMEN

Use unhemolysed serum or plasma. Plasma specimens may obtain 0.4 g/dl high due to fibrinogen. Serum/ plasma is stable for 7 days at 2-8 °C and 1 month at -20 °C.

#### Programme Parameter for MERILYZER CliniQuant

Reading Mode	End Point
Standard Conc.	6 (g/dl)
Filter - 1 (nm)	546
Temperature	37 °C
Volume ( µl)	500
Delay Time (Sec)	5
Reaction Direction	Increase
Reference Low	6.0
Reference High	8.3
Linearity Limit	15



## Total protein

### TEST PROCEDURE

Dispense	Blank	Standard	Sample
Reagent 1	1ml	1ml	1ml
Distilled water	20 µl	-	-
Standard	-	20 µl	-
Sample	-	-	20 µl

Mix, incubate for 5 min at 37°C. Read absorbance of standard (As) and samples (Ax) against reagent blank.

### RESULT CALCULATION

Serum/plasma:

Proteins g/dl =  $A_x/A_s \times \text{Concentration of Standard}$

SI conversion factor:  $1 \text{ g/dl} \times 10 = 1 \text{ g/l}$

### EXPECTED VALUES

6.0 – 8.3 g/dl OR 60 – 83 g/l

It is recommended that each laboratory verifies this range or derives reference interval for the population it serves.

### QUALITY CONTROL AND CALIBRATION

It is recommended to perform internal quality control with assayed normal (BioNorm) and assayed abnormal (BioPath), to confirm the validity of the test and assure the accuracy of patient result.

Using the recommended Calibrator (BioCal) or the Standard included, calibrate the assay:

- When using a new reagent or lot
- When QC values are out of range

### PERFORMANCE CHARACTERISTICS

#### 1. Linearity

The linearity is up to 15.0 g/dl.

#### 2. Sensitivity/ Limit of detection (LOD)

The limit of detection is 0.05 g/dl.

The limit of quantification is 0.1 g/dl.

### 3. Interferences

Gross hemolysis, lipaemia and icteric specimens may cause falsely elevated results, a sample blank be set by adding 20 µl sample in 1ml saline.

### 4. Precision

Intra-assay precision

	Mean	SD	CV
n = 20	g/dl	g/dl	%
sample 1	6.66	0.02	0.33
sample 2	4.91	0.03	0.62

Inter-assay precision

	Mean	SD	CV
n = 20	g/dl	g/dl	%
sample 1	6.52	0.24	3.70
sample 2	4.83	0.22	4.50

### 5. Methods Comparison

Comparison was done between reference Total Protein Reagent and CliniQuant - FSR Total Protein Reagent (test)

$N = 36$        $y = 0.973x + 0.267$

$r^2 = 0.963$

### LIMITATIONS

Samples with values above 15 g/dl should be diluted with 0.9% saline, re-run and results multiplied by dilution factor.

### WASTE DISPOSAL

This product is made to be used in professional laboratories. Please consult local regulations for correct waste disposal.











### REFERENCES


- Burtis, C.A., Ashwood, E.R., editors. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia, W.B. Saunders Company, 1994, p. 695 – 700.
- Data on file: Meril Diagnostics.

IFU/TPRFSR01/00

06-11-2018

Symbols used on Meril Diagnostics labels:

 Catalogue No.	 Attention See Instruction for Use
 Batch No.	 <i>in vitro</i> Diagnostics
 Expiry Date	 Consult Instruction for Use
 Manufacturer	 Storage Temperature
 Keep Dry	 Keep Away from Sunlight
 Manufacturing Date	 Do not use if package is damaged

 Authorized European Representative in the European Community

## Appendix 13 GOT

### SGOT Kit CliniQuant - FSR IFCC Method, Kinetic



For in vitro diagnostic use  
Read this pack insert thoroughly before use

REF	Pack Size	R1 SGOT Reagent	R2 SGOT Reagent
GOTFSR-01	4 x 20 / 4 x 5ml	4 x 20ml	4 x 5ml
GOTFSR-02	4 x 100 / 2 x 50ml	4 x 100ml	2 x 50ml


#### INTENDED USE

This reagent is intended for quantitative determination of SGOT level in human serum.

#### CLINICAL SIGNIFICANCE

The aminotransferases (transaminases) are widely distributed in animal tissues. Both AST & ALT are normally present in human plasma, bile, cerebrospinal fluid, and saliva. Elevated AST levels are observed in viral hepatitis and other liver disease, cirrhosis, myocardial infarction.

#### PRINCIPLE OF THE METHOD



AST: Aspartate aminotransferase

MDH: Malate dehydrogenase

LDH: Lactate dehydrogenase

#### KIT COMPONENTS

##### Composition

R1 - SGOT Reagent : Tris buffer 20 mmol/l pH 7.8, L-Asparatic acid 231 mmol/l, MDH > 0.2 KU/l, LDH > 4 KU/l, 2-oxoglutarate 17.17 mmol/l

R2 - SGOT Reagent : NADH 0.18 mmol/l, 2-oxoglutarate 15 mmol/l

#### MATERIALS REQUIRED BUT NOT PROVIDED

Laboratory instrumentation, Spectrophotometer UV/VIS with thermostatic cuvette holder or clinical chemistry analyzer: semi automated, calibrated micropipettes, glass or high quality polystyrene cuvettes, test tube/ rack, heating bath, controls, saline.

#### REAGENT PREPARATION, STORAGE & STABILITY

Mix reagent 1 & reagent 2 in ratio 4:1. Keep away from direct light sources.

Stability: up to expiration date on labels at 2-8 °C.

Stability of working reagent: 30 days at 2-8 °C.

#### REAGENT DETERIORATION

Discard the working reagent if absorbance < 1.0 at 340 nm against distilled water.

#### WARNINGS AND PRECAUTIONS

1. Reagent may contain some non-reactive and preservative components. It is recommended to handle carefully, avoiding contact with skin and ingestion.
2. Specimens should be considered infectious and handled appropriately.
3. Perform the test according to the general "Good Laboratory Practice" (GLP) guidelines.

#### SPECIMEN

Use serum, plasma. SGOT is stable for 4 days at 2-8 °C or 1 month at -20°C.

#### Programme Parameter for MERILYZER CliniQuant

Procedure	Assay protocol1:	Assay protocol2:
	Normal	High linearity
Reading Mode	Rate	Rate
Factor	1768	1768
Filter- 1(nm)	340	340
Temperature	37 °C	37 °C
Volume ( µl)	450	450
Delay Time (Sec)	60	30
Read Time (Sec)	120	60
Unit	U/l	U/l
Reaction Direction	Decrease	Decrease
Reference Low	0	0
Reference High	45	45
Linearity Limit	450	1600



Meril Diagnostics Pvt. Ltd., Second Floor, D1-D3, Meril Park, Survey No. 135/2/B & 174/2, Muktanand Marg, Chala, Vapi-396191, Gujarat, India. T+91-260-3052100, F +91-260-3052126, W www.merillife.com

OBELIS s.a., Bd General Wahis 53, 1030, Brussels, Belgium. T +(32) 2 732-59-54, F +(32) 2 732-60-03, E mail@obelis.net

## . GOT

**TEST PROCEDURE**

Dispense in tube : working reagent	500 µl
Add Sample	50 µl
Assay Protocol1: Mix and incubate 60 seconds at 37°C, then record first reading of absorbance. Perform other 2 readings at 60 seconds intervals. Calculate the $\Delta A/\text{min}$ .	

Assay Protocol2: Mix and incubate 30 seconds at 37°C, then record first reading of absorbance. Perform other 2 readings at 30 seconds intervals. Calculate the $\Delta A/\text{min}$ .	
---	--

**RESULT CALCULATION**

Perform calculations in units per litre, multiplying the  $\Delta A/\text{min}$  by the factor.

Activity in U/l =  $\Delta A/\text{min} \times 1768$

SI conversion factor: 1 U/l  $\times$  0.017 = 1 µkat/l

**EXPECTED VALUES**

< 45 U/l at 37°C OR 0.8 µkat/l

It is recommended that each laboratory verifies this range or derives reference interval for the population it serves.

**QUALITY CONTROL AND CALIBRATION**

It is suggested to perform internal quality control with assayed normal (BioNorm) and assayed abnormal (BioPath), to confirm the validity of the test and assure the accuracy of patient result.

When using the recommended Calibrator (BioCal), calibrate the assay:

- When using a new reagent or lot
- When QC values are out of range

**PERFORMANCE CHARACTERISTICS****1. Linearity**

As per assay protocol1: Linearity is up to 450 U/l or 7.7 µkat/l.

As per assay protocol2: Linearity is up to 1600 U/l or 27.2 µkat/l

**2. Sensitivity/ Limit of detection (LOD)**

The limit of detection is 1 U/l

The limit of quantification is 4 U/l.

**3. Interferences**

No interference has been observed for the following Hemoglobin up to 70 mg/dl; Bilirubin up to 40 mg/dl Triglyceride up to 1000 mg/dl

**4. Precision**

Intra-assay precision

	Mean	SD	CV
n = 20	U/l	U/l	%
sample 1	46.94	0.43	0.92
sample 2	137.49	0.78	0.57

Inter-assay precision

	Mean	SD	CV
n = 20	U/l	U/l	%
sample 1	49.86	2.41	4.84
sample 2	143.33	2.36	1.65

**5. Methods Comparison**

Comparison was done between reference AST (SGOT) Reagent and CliniQuant - FSR SGOT Reagent (test)

N = 36  $y = 0.967x + 6.082$

$r^2 = 0.946$

**LIMITATIONS**

Samples with values above 1600 U/l should be diluted with 0.9% saline, re-run and results multiplied by dilution factor

**WASTE DISPOSAL**

This product is made to be used in professional laboratories. Please consult local regulations for correct waste disposal.

**REFERENCES**

- Burtis, C.A., Ashwood, E.R., editors. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia, W.B. Saunders Company, 1994, p. 790 - 795.
- Data on file: Meril Diagnostics.

IFU/GOTFSR01/00

06-11-2018

Symbols used on Meril Diagnostics labels:

	Catalogue No.		Attention See Instruction for Use
	Batch No.		In vitro Diagnostics
	Expiry Date		Consult Instruction for Use
	Manufacturer		Storage Temperature
	Keep Dry		Keep Away from Sunlight
	Manufacturing Date		Do not use if package is damaged
	Authorized European Representative in the European Community		



# Appendix 14. ALP

## Alkaline Phosphatase Kit

### CliniQuant - FSR



#### Modified IFCC, Kinetic

For in vitro diagnostic use  
Read this pack insert thoroughly before use

REF	Pack Size	R1 ALP Reagent
ALPFSR-01	4 x 10ml	4 x 10ml
ALPFSR-02	5 x 20ml	5 x 20ml

#### INTENDED USE


This reagent is intended for quantitative determination of alkaline phosphatase in human serum.

#### CLINICAL SIGNIFICANCE

ALP occurs in high levels in liver, bone, intestine and placenta. Increased levels occur in hepatobiliary diseases and bone diseases. Elevated ALP occurs in pregnant women and growing children.

#### PRINCIPLE OF THE METHOD

The enzyme alkaline phosphatase hydrolyzes the 4-NitroPhenolPhosphate to release 4-nitrophenol, under alkaline conditions. The 4-nitrophenol formed is detected spectrophotometrically at 405 nm to give a measurement of alkaline phosphatase activity in the sample.



#### KIT COMPONENTS

##### Composition

R1 - Alkaline Phosphatase Reagent : AMP buffer 700 mmol/l , magnesium salt 2.7 mmol/l, zinc salt 1.36mmol/l, HEDTA 2 mmol/l : 2.69mmol/l, pNPP 19.51 mmol/l.

#### MATERIALS REQUIRED BUT NOT PROVIDED

Laboratory instrumentation, Spectrophotometer UV/VIS with thermostatic cuvette holder or clinical chemistry analyzer: semi automated, calibrated micropipettes, glass or high quality polystyrene cuvettes, test tubes/rack, heating bath, controls, saline.

#### REAGENT PREPARATION, STORAGE & STABILITY

Reagent is ready to use. Keep away from direct light sources.

Stability: up to expiration date on labels at 2-8 °C.

Stability since first opening of bottle: < 60 days at 2-8 °C.

#### REAGENT DETERIORATION

Discard the reagent if absorbance exceeds 1.25 against distilled water at 405 nm.

#### WARNINGS AND PRECAUTIONS

1. Reagent may contain some non-reactive and preservative components. It is suggested to handle carefully, avoiding contact with skin and ingestion.
2. Specimens should be considered infectious and handled appropriately.
3. Perform the test according to the general "Good Laboratory Practice" (GLP) guidelines.

#### SPECIMEN

Serum, plasma (heparinate only). Sera kept at room temperatures usually show a slight increase in activity, which varies from 1% over a 6 hour period to 3 to 6% over a 1 to 4 days period. Even in sera stored at refrigerator temperature, activity increases slowly. In frozen sera, activity decreases but slowly recovers after thawing the serum. EDTA, Citrate, and Oxalate are not suitable because of inhibition of ALP activity.

#### Programme Parameter for MERILYZER CliniQuant

Reading Mode	Rate
Factor	2764
Filter - 1 (nm)	405
Temperature	37 °C
Volume (µl)	500
Delay Time (Sec)	60
Read Time (Sec)	120
Unit	U/L
Reaction Direction	Increase
Reference Low	42
Reference High	128
Linearity Limit	1200

#### TEST PROCEDURE

Dispense reagent in tube	1000 µl
Sample	20 µl
Mix, execute a first reading of absorbance after 1 minute, incubating at 37°C. Perform other 2 readings at 60 seconds intervals. Calculate the ΔA/min.	



Meril Diagnostics Pvt. Ltd., Second Floor, D1-D3, Meril Park, Survey No. 135/2/B & 174/2, Muktanand Marg, Chala, Vapi-386191, Gujarat, India. T+91-260-3052100, F -91-260-3052125, W www.merilife.com



Obelis s.a., Bd General Wahis 53, 1030, Brussels, Belgium. T +(32) 2 732-59-54, F +(32) 2 732-60-03, E mail@obelis.net

## ALP

### RESULT CALCULATION

Serum/plasma: ALP U/l =  $\Delta A/\text{min} \times 2764$

SI conversion factor: 1 U/l  $\times 0.017 = 1 \mu\text{kat/l}$

### CONVERSION FACTOR

Following factors can be used for conversion of IU/l from one temperature to another.

Temperature of assay	Temperature factors		
	25°C	30°C	37°C
25°C	1.0	1.30	1.80
30°C	0.75	1.0	1.35
37°C	0.55	0.74	1.0

### EXPECTED VALUES (in U/l at 37°C)

Age	Males	Females
Newborns (1-3 days)	95 – 368	95 – 368
2 – 24 months	115 – 460	115 – 460
2 – 5 years	115 – 391	115 – 391
6 – 7 years	115 – 460	115 – 460
8 – 9 years	115 – 345	115 – 345
10 – 11 years	115 – 336	115 – 437
12 – 13 years	127 – 403	92 – 336
14 – 15 years	79 – 446	78 – 212
16 – 18 years	58 – 331	35 – 124
Adults	41 – 137	39 – 118

It is recommended that each laboratory verifies this range or derives reference interval for the population it serves.

### QUALITY CONTROL AND CALIBRATION

It is recommended to perform internal quality control with assayed normal (BioNorm) and assayed abnormal (BioPath), to confirm the validity of the test and assure the accuracy of patient result. When using the recommended Calibrator (BioCal), calibrate the assay:

- When using a new reagent or lot
- When QC values are out of range

### PERFORMANCE CHARACTERISTICS

#### 1. Linearity

The linearity is up to 1200 U/l or 20.4  $\mu\text{kat/l}$ .

#### 2. Sensitivity/ Limit of detection (LOD)

The limit of detection is 1.8 U/l.

The limit of quantification is 5.5 U/l.

#### 3. Interferences

No interference has been observed for the following  
Hemoglobin up to 1200 mg/dl; Bilirubin up to 10 mg/dl  
Triglycerides up to 1900 mg/dl; Ascorbate up to 30 mg/dl

#### 4. Precision

Intra-assay precision

	Mean	SD	CV
n = 20	U/l	U/l	%
sample 1	81.7	1.08	1.32
sample 2	208.5	1.73	0.83

Inter-assay precision

	Mean	SD	CV
n = 20	U/l	U/l	%
sample 1	85.0	2.8	3.3
sample 2	207	2.89	1.4

#### 5. Methods Comparison

Comparison was done between reference ALP Reagent and Cliniquant -FSR Alkaline Phosphatase Reagent (test)

N = 20  $y = 0.962x - 3.622$  U/l

$r^2 = 0.999$

#### LIMITATIONS

Samples with values above 1200 U/l should be diluted with 0.9% saline, re-run and results multiplied by dilution factor

#### WASTE DISPOSAL

This product is made to be used in professional laboratories. Please consult local regulations for correct waste disposal

#### REFERENCES

- Burtis, C.A., Ashwood, E.R., editors. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia, W.B. Saunders Company, 1994, p. 830 - 843.
- Data on file: Meril Diagnostics.

IFU/ALPFSR01/00

06-11-2018

Symbols used on Meril Diagnostics labels:

 Catalogue No.	 Attention See Instruction for Use
 Batch No.	 In vitro Diagnostics
 Expiry Date	 Consult Instruction for Use
 Manufacturer	 Storage Temperature
 Keep Dry	 Keep Away from Sunlight
 Manufacturing Date	 Do not use if package is damaged
 Authorized European Representative in the European Community	

## Appendix 15. Glucose

### Glucose Kit

### CliniQuant – FSR

#### Trinder's Method, End Point



For *in vitro* diagnostic use  
Read this pack insert thoroughly before use

REF	Pack Size	R1 Glucose Reagent	R2 Glucose Standard
GLUFSR-01	4 x 50ml	4 x 50ml	1 x 5ml
GLUFSR-02	5 x 100ml	5 x 100ml	1 x 5ml
GLUFSR-03	4 x 250ml	4 x 250ml	2 x 5ml
GLUFSR-04	4 x 500ml	4 x 500ml	2 x 5ml

#### INTENDED USE


This reagent is intended for quantitative determination of glucose concentration in human serum or plasma.

#### CLINICAL SIGNIFICANCE

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, hypoglycaemia and various other conditions.

#### PRINCIPLE OF THE METHOD

Glucose in the sample is oxidised to yield gluconic acid and hydrogen peroxide in the presence of Glucose oxidase. The enzyme peroxidase catalyses the oxidative coupling of 4-aminoantipyrine with phenol to yield a coloured quinonimine complex, with absorbance proportional to the concentration of glucose in sample.



#### KIT COMPONENTS

##### Composition

R1 - Glucose Reagent: Dipotassium hydrogen phosphate 21.7 g/l, Potassium dihydrogen phosphate 10.2 g/l, 4-AAAP 0.081 g/l, Phenol 0.282 g/l, Peroxidase 0.8ku/l, Glucose oxidase 15 ku/l, Sodium glutamate 15 g/l, p-Chloro meta cresol 0.01 %, Sodium Azide 0.025 %  
R2 - Glucose Standard : 100 mg/dl, Benzoic acid 0.2 %, Dextrose 1 g/l

#### MATERIALS REQUIRED BUT NOT PROVIDED

Laboratory instrumentation, Spectrophotometer UV/VIS with thermostatic cuvette holder or clinical chemistry analyzer: semi automated, calibrated micropipettes, glass or high quality polystyrene cuvettes, test tube/ rack, heating bath, controls, saline.

#### REAGENT PREPARATION, STORAGE & STABILITY

Reagent is ready to use. Keep away from direct light sources.

Stability: up to expiration date on labels at 2-8 °C.

Stability since first opening of bottle: preferable within 60 days at 2-8 °C.

#### REAGENT DETERIORATION

1. Discard the reagent if absorbance exceeds 0.3 against distilled water.

2. Keep the Standard vial plugged after use, in order to avoid deterioration.

#### WARNINGS AND PRECAUTIONS

1. Reagent may contain some non-reactive and preservative components. It is suggested to handle carefully, avoiding contact with skin and ingestion.
2. Specimens should be considered infectious and handled appropriately.
3. Perform the test according to the general "Good Laboratory Practice" (GLP) guidelines.

#### SPECIMEN

Use fresh unhaemolysed serum. The stability of glucose in specimen is reduced by bacterial contamination and by glycolysis. Serum or plasma should be separated from the cells, as soon as possible, to prevent glycolysis. The addition of sodium fluoride is recommended to inhibit glycolysis. Serum / plasma is stable for 3 days at 2-8 °C. It is recommended to perform the assay with freshly collected samples, as glycolysis decreases serum glucose by approximately 5 to 10 mg/dl in 1 hr in normal uncentrifuged coagulated blood at room temperature.

#### Programme Parameter for MERILYZER CliniQuant

Assay protocol1: Normal	
Reading Mode	End Point
Standard Conc.	100 (mg/dl)
Filter – 1 (nm)	505
Filter – 2 (nm)	620
Temperature	37 °C
Volume ( µl)	500
Delay Time (Sec)	5
Reaction Direction	Increase
Reference Low	70
Reference High	110
Linearity Limit	500

Assay protocol2: High linearity	
Reading Mode	Fixed Time
Standard Conc.	100 (mg/dl)
Filter – 1 (nm)	505
Temperature	37 °C
Volume (µl)	500
Delay Time (Sec)	30
Read Time (Sec)	60
Reaction Direction	Increase
Reference Low	70
Reference High	110
Linearity Limit	800



## Glucose

### TEST PROCEDURE

#### Assay Protocol1:

Dispense	Blank	Standard	Sample
Reagent 1	1ml	1ml	1ml
Distilled water	10 µl	-	-
Standard	-	10 µl	-
Sample	-	-	10 µl

Mix, incubate for 10 min at 37°C. Read absorbance of standard (As) and samples (Ax) against reagent blank.

#### Assay Protocol2:

Dispense	Standard	Sample
Reagent 1	1000 µl	1000 µl
Standard	10 µl	-
Sample	-	10 µl

Mix, incubate 30 seconds at 37°C, then record absorbance as A1. After exactly 60 seconds, record again absorbance as A2.

### RESULT CALCULATION

Serum/plasma:

Glucose mg/dl =  $Ax/As$  x Concentration of Standard

or

Glucose mg/dl =  $A2-A1(\text{sample})/A2-A1(\text{standard})$  x concentration of Standard.

SI conversion factor: 1 mg/dl x 0.0555 = 1 mmol/l

### EXPECTED VALUES

Glucose Fasting: 70 - 110 mg/dl OR 3.8 - 6.1 mmol/l  
 Post Prandial: 90 - 140 mg/dl OR 5.0 - 7.8 mmol/l

It is recommended that each laboratory verifies this range or derives reference interval for the population it serves.

### QUALITY CONTROL AND CALIBRATION

It is recommended to perform internal quality control with assayed normal (BioNorm) and assayed abnormal (BioPath), to confirm the validity of the test and assure the accuracy of patient result.

Using the recommended Calibrator (BioCal) or the Standard included, calibrate the assay:

- When using a new reagent or lot
- When QC values are out of range

### PERFORMANCE CHARACTERISTICS

#### 1. Linearity

As per assay protocol1: The linearity is up to 500 mg/dl (27.5 mmol/l).

As per assay protocol2: The linearity is up to 800 mg/dl (44 mmol/l).

### 2. Sensitivity/ Limit of detection (LOD)

The limit of detection is 4 mg/dl (0.22 mmol/l).

The limit of quantification is 13 mg/dl (0.72 mmol/l).

### 3. Interferences

No interference has been observed for the following Hemoglobin up to 750mg/dl; Bilirubin up to 20 mg/dl Triglycerides up to 500 mg/dl

### 4. Precision

#### Intra-assay precision

	Mean	SD	CV
n = 20	mg/dl	mg/dl	%
sample 1	97.77	0.61	0.63
sample 2	261.55	1.32	0.50

#### Inter-assay precision

	Mean	SD	CV
n = 20	mg/dl	mg/dl	%
sample 1	92.41	4.47	4.84
sample 2	252.24	2.77	1.16

### 5. Methods Comparison

Comparison was done between reference Glucose Reagent and CliniQuant - FSR Glucose Reagent (test)

N = 23       $y = 0.961x + 13.74$

$r^2 = 0.987$

### LIMITATIONS

Samples with values above 800 mg/dl should be diluted with 0.9% saline, re-run and multiply results by dilution factor.

### WASTE DISPOSAL

This product is made to be used in professional laboratories. Please consult local regulations for correct waste disposal.

### REFERENCES

- Thomas L.: Clinical Laboratory Diagnostics, 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998, p. 131 - 7.
- Sacks, D.B.: Carbohydrates. In: Burtis, C.A., Ashwood, E.R., editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, W.B. Saunders Company, 1999, p. 750 - 808.
- Barham, D., Trinder, P.: An improved color reagent for the determination of blood glucose by the oxidase system. Analyst, 1972, 97; 142 - 5.
- Data on file: Meril Diagnostics.

IFU/GLUF SR01/00

06-11-2018

Symbols used on Meril Diagnostics labels:

 Catalogue No.	 Attention See Instruction for Use
 Batch No.	 In vitro Diagnostics
 Expiry Date	 Consult Instruction for Use
 Manufacturer	 Storage Temperature
 Keep Dry	 Keep Away from Sunlight
 Manufacturing Date	 Do not use if package is damaged
 Authorized European Representative in the European Community	


## Appendix 16 LDH

LDH BR 

<b>REF 1141010</b> 2 x 50 mL <b>CONTENTS</b> R1. Reagent 2 x 40 mL R2. Reagent 1 x 20 mL For <i>in vitro</i> diagnostic use only	<b>LDH BR</b> SFBC <i>UV enzymatic method</i> KINETIC
---	--

**PRINCIPLE**

Lactate dehydrogenase (LD/LDH) catalyzes the reduction of pyruvate to lactate (P-L) in the presence of reduced nicotinamide adenine dinucleotide (NADH) at pH 7.5. The reaction is monitored kinetically at 340 nm by the rate of decrease in absorbance resulting from the oxidation of NADH to NAD<sup>+</sup> proportional to the activity of LD present in the sample.




This test has been formulated according to the standardized method described by SFBC.<sup>1</sup>

**REAGENT COMPOSITION**

**R1** LDH substrate. TRIS buffer 100 mmol/L pH 7.5, pyruvate 2.75 mmol/L, sodium chloride 222 mmol/L.

**R2** LDH coenzyme. NADH 1.55 mmol/L.

**STORAGE AND STABILITY**

 Store at 2-8°C.

All the kit compounds are stable until the expiry date stated on the label. Do not use reagents over the expiration date. Store the vials tightly closed, protected from light and prevented contaminations during the use.

**Discard if appear signs of deterioration:**

- Presence of particles and turbidity.
- Blank absorbance (A) at 340 nm < 1.000 in 1 cm cuvette.

**REAGENT PREPARATION**

**Working reagent.** Mix 4 mL of **R1** + 1 mL of **R2**. Stable for 2 months at 2-8°C.  
Protected from light.

**SAMPLES**

Serum free of hemolysis separated from the cells as soon as possible after collection. The use of heparin and citrate as anticoagulants have been reported to falsely elevate LD activity. Freezing results in loss of activity of the enzyme.

**INTERFERENCES**

- Lipemia (intralipid > 20 g/L) does not interfere.
- Bilirubin (> 40 mg/dL) does not interfere.
- Hemoglobin (> 4 g/L) may affect the results.
- Other drugs and substances may interfere<sup>3</sup>.

**MATERIALS REQUIRED**

- Photometer or spectrophotometer with a thermostatted cell compartment set at 30/37°C, capable of reading at 340 nm.
- Stopwatch, strip-chart recorder or printer.
- Cuvettes with 1-cm pathlength.
- Pipettes to measure reagent and samples.

**PROCEDURE**

1. Preincubate working reagent, samples and controls to reaction temperature 30/37°C.
2. Set the photometer to 0 absorbance with distilled water.
3. Pipette into a cuvette:

Reaction temperature	30/37°C
Working reagent	1.0 mL
Sample or control	20 µL


4. Mix gently by inversion. Insert cuvette into the cell holder and start stopwatch.
5. Incubate for 30 seconds and record initial absorbance reading.
6. Repeat the absorbance readings exactly after 1, 2 and 3 minutes.
7. Calculate the difference between absorbances.
8. Calculate the mean of the results to obtain the average change in absorbance per minute (ΔA/min).

**CALCULATIONS**

$$U/L = \Delta A/\text{min} \times 8095$$

Samples with ΔA/min exceeding 0.150 at 340 nm should be diluted 1:10 with saline and assayed again. Multiply the results by 10.

If results are to be expressed as SI units apply:  
 $U/L \times 0.01667 = \mu\text{kat/L}$



LINEAR CHEMICALS, S.L.U. Joaquim Costa 18 2ª planta. 08390 Montgat (Barcelona) SPAIN  
 Telf. (+34) 934 694 990; E-mail: [info@linear.es](mailto:info@linear.es); website: [www.linear.es](http://www.linear.es) NIF-VAT:B60485687



LDH

LINEAR

**REFERENCE VALUES<sup>1</sup>**

Serum

Temperature	37°C	30°C
Adults	207 - 414 U/L (3.40 - 6.80 µkat/L)	140 - 280 U/L (2.30 - 4.70 µkat/L)

It is recommended that each laboratory establishes its own reference range.

**QUALITY CONTROL**

To ensure adequate quality control (QC), each run should include a set of controls (normal and abnormal) with assayed values handled as unknowns.

**REF 1980005 HUMAN MULTISERA NORMAL**  
Borderline level of LDH. Assayed.

**REF 1985005 HUMAN MULTISERA ABNORMAL**  
Elevated level of LDH. Assayed.

If the values are found outside of the defined range, check the instrument, reagents and procedure.

Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances.

**CLINICAL SIGNIFICANCE<sup>2,5</sup>**

The enzyme activity found in circulation is a mixture of five isoenzymes. Each organ has a characteristic isoenzyme profile. Leakage of these isoenzymes from a diseased organ results in the elevation of total serum LD.

*Increased* levels become evident 8-12 hours after myocardial infarction reaching a maximum 4-5 days later. Elevated values in serum are also encountered in cases of pulmonary embolism and in about one third of patients with renal disease, specially those with pyelonephritis or tubular necrosis. In toxic hepatitis with jaundice, Hodgkin's disease and abdominal and lung cancers elevations are specially high.

*Moderate* increases are also observed in cases of liver disease, megaloblastic and pernicious anemia and progressive muscular dystrophy.

*Decreases* are not important clinically.

**ANALYTICAL PERFORMANCE**

- **Detection Limit** : 15.73 U/L

- **Linearity** : Up to 1500 U/L

- **Precision**:

U/L	Within-run		Between-run	
Mean	495	879	495	879
SD	4.32	7.34	14	13.5
CV%	0.87	0.83	2.83	1.54
N	10	10	10	10

- **Sensitivity** : 0.152 mA / U/L LDH

- **Correlation**: This assay (y) was compared with a similar commercial method (x). The results were:

$$N = 52 \quad r = 0.99 \quad y = 1.031x + 3.147$$

The analytical performances have been generated using an automatic instrument. Results may vary depending on the instrument.

QUALITY SYSTEM CERTIFIED  
ISO 9001 ISO 13485



LINEAR CHEMICALS, S.L.U. Joaquim C  
Telf. (+34) 934 694 990; E-mail: [info@linear.es](mailto:info@linear.es); website: [www.linear.es](http://www.linear.es) NIF-VAT:B60485687

EL141-2/001  
R1.1ng

**NOTES**

1. This method may be used with different instruments. Any application to an instrument should be validated to demonstrate that results meets the performance characteristics of the method. It is recommended to validate periodically the instrument. Contact to the distributor for any question on the application method.

2. Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

**REFERENCES**

1. Comission Enzymologie de la Societé Française de Biologie Clinique. Ann. Biol. Clin. 40: 123-128 (1982).
2. Sociedad Española de Química Clínica, Comité Científico, Comisión de Enzimas. Método recomendado para la determinación en rutina de la concentración catalítica de lactato deshidrogenada en suero sanguíneo humano. *Quim Clin* 1988; 8:57-61.
3. Young DS. Effects of drugs on clinical laboratory tests, 4th ed. AACC Press, 1995.
4. Tietz, N.W. Clinical Guide to Laboratory Tests, 3<sup>rd</sup> Edition. W.B. Saunders Co. Philadelphia, PA. (1995).
5. Friedman and Young. Effects of disease on clinical laboratory tests, 5<sup>th</sup> ed. AACC Press, 2000.


### Appendix 17: Statistical data for Effect of CuNPs against *Ae. aegypti* larvae

Estimation of Probit Line, LC50/LD50 and Fit statistics

Mean X	13.208	<b>UL</b>	<b>13.482</b>
Mean Y	0.493	Log (LC50)	0.847
Intercept	-1.523	Log LL	0.564
Beta	1.799	Log UL	1.130
<b>LC50</b>	<b>5.787</b>	Chi-Square ML	1.573
Sign Chi-Square	0.203	<b>LL</b>	<b>3.662</b>

Estimation of LC50/LD50 with Confidence interval

Percent	Probit	95 % Confidence Limit for Conc			Variance	95 % Confidence Limit for log (Conc)		
		LC	LL	UL		Log LC	Log LL	Log UL
10.000	-1.282	1.362	0.710	2.614	0.043	0.134	-0.149	0.417
30.000	-0.524	3.591	1.872	6.890	0.019	0.555	0.272	0.838
50.000	0.000	5.787	3.662	13.482	0.011	0.847	0.564	1.130
75.000	0.674	16.662	8.684	31.967	0.008	1.222	0.939	1.505
90.000	1.282	36.581	18.889	69.532	0.015	1.559	1.276	1.842
99.000	2.326	138.045	71.951	264.853	0.045	2.140	1.857	2.423




### Appendix 18: Statistical data for Effect of Green Coffee against *Ae. aegypti* larvae

Estimation of Probit Line, LC50/LD50 and Fit statistics

Mean X	19.205	LL	95.143
Mean Y	0.383	UL	162.984
Intercept	-1.523	Log (LC50)	2.095
Beta	3.798	Log LL	1.978
LC50	124.526	Log UL	2.212
Sign Chi-Square	0.090	Chi-Square ML	6.482

Estimation of LC50/LD50 with Confidence interval

Percent	Probit	95 % Confidence Limit for Conc			Variance	95 % Confidence Limit for log (Conc)		
		LC	LL	UL		Log LC	Log LL	Log UL
10.000	-1.282	33.965	25.950	44.454	0.016	1.531	1.414	1.648
30.000	-0.524	73.178	55.911	95.778	0.007	1.864	1.747	1.981
<b>50.000</b>	<b>0.000</b>	<b>124.526</b>	<b>95.143</b>	<b>162.984</b>	<b>0.003</b>	<b>2.095</b>	<b>1.978</b>	<b>2.212</b>
75.000	0.674	246.729	188.511	322.927	0.001	2.392	2.275	2.509
<b>90.000</b>	<b>1.282</b>	<b>456.555</b>	<b>348.826</b>	<b>597.554</b>	<b>0.003</b>	<b>2.659</b>	<b>2.543</b>	<b>2.776</b>
99.000	2.326	1,316.705	1,006.015	1,723.347	0.014	3.119	3.003	3.236






### Appendix 19: Statistical data for Effect of Roasted Coffee against *Ae. aegypti* larvae

Estimation of Probit Line, LC50/LD50 and Fit statistics

Mean X	13.208	LL	51.382
Mean Y	0.493	UL	104.995
Intercept	-1.523	Log (LC50)	1.866
Beta	1.799	Log LL	1.711
LC50	73.450	Log UL	2.021
Sign Chi-Square	0.203	Chi-Square ML	4.610

Estimation of LC50/LD50 with Confidence interval

Percent	Probit	95 % Confidence Limit for Conc			Variance	95 % Confidence Limit for log (Conc)		
		LC	LL	UL		Log LC	Log LL	Log UL
10.000	-1.282	33.965	25.950	44.454	0.016	1.531	1.414	1.648
30.000	-0.524	3.591	1.872	6.890	0.019	0.555	0.272	0.838
50.000	0.000	5.787	3.662	13.482	0.011	0.847	0.564	1.130
75.000	0.674	16.662	8.684	31.967	0.008	1.222	0.939	1.505
90.000	1.282	36.581	18.889	69.532	0.015	1.559	1.276	1.842
99.000	2.326	138.045	71.951	264.853	0.045	2.140	1.857	2.423




### Appendix 20: Statistical data for Effect of CuNPs against *Artemia salina* larvae

Estimation of Probit Line, LC50/LD50 and Fit statistics

Mean X	292.046	LL	275.990
Mean Y	-0.185	UL	429.479
Intercept	-6.584	Log (LC50)	2.537
Beta	2.595	Log LL	2.441
LC50	344.285	Log UL	2.633
Sign Chi-Square	0.715	Chi-Square ML	1.361

Estimation of LC50/LD50 with Confidence interv

Percent	Probit	95 % Confidence Limit for Conc			Variance	95 % Confidence Limit for log (Conc)		
		LC	LL	UL		Log LC	Log LL	Log UL
10.000	-1.282	110.444	88.536	137.774	0.004	2.043	1.947	2.139
30.000	-0.524	216.207	173.318	269.708	0.001	2.335	2.239	2.431
<b>50.000</b>	<b>0.000</b>	<b>344.285</b>	<b>275.990</b>	<b>429.479</b>	<b>0.001</b>	<b>2.537</b>	<b>2.441</b>	<b>2.633</b>
75.000	0.674	626.319	502.078	781.303	0.003	2.797	2.701	2.893
<b>90.000</b>	<b>1.282</b>	<b>1,073.231</b>	<b>860.338</b>	<b>1,338.806</b>	<b>0.007</b>	<b>3.031</b>	<b>2.935</b>	<b>3.127</b>
99.000	2.326	2,711.739	2,173.820	3,382.768	0.019	3.433	3.337	3.529



## CURRICULUM VITAE

### A. Personal Data

1. Full name: Yousef Abdulwahab Abdullah Ahmed
2. Place and date of birth: Yemen, March 17<sup>th</sup>, 1979
3. Nationality: Yemen
4. Address: 26 street, Taiz, Yemen
5. Status: Married



### B. Educational background

1. Elementary school year 1990 in Al-Faruk school, Taiz, Yemen
2. secondary school year 1993 in Al-Rashed school, Taiz, Yemen
3. Bachelor degree year 1998 in Taiz University, Taiz, Yemen
4. Master degree year 2011 in Taiz University, Taiz, Yemen

### C. Professional/work Experiences

1. Institutions: Taiz University, Yemen
2. NIP: 04010249624
3. Occupation: Research Assistant

### D. Published papers / articles

1. "Histopathological and Biochemical Alteration of Liver in Albino Mice Experimentally Infected by Visceral Leishmaniasis in Taiz-Yemen" 2013, Egypt. J. Zool., 60: 131 – 142, <http://doi.org/10.12816/0003287>
2. " Histopathological and biochemical alterations of kidneys in albino mice infected by Visceral leishmaniasis and the role of *Aloe vera* crude" 2018, AL-Saeed Journal of Humanities and Applied Sciences Volume 2, Yemen, <http://doi.org/10.59325/sjhas.v2i1.49>
3. " A Review on Phytochemical and Pharmacological Properties of *Coffee arabica* Plant", Journal of Chemistry and Nutritional Biochemistry 3.1 (2022): 24-36. <http://doi.org/10.48185/jcnb.v3i1.543>
4. "Green Synthesis of Copper Nanoparticles Mediated from *Coffee arabica* Seeds Extract" Rasayan J. Chem., 16(3), 1217-1228 (2023) <http://doi.org/10.31788/RJC.2023.1638417>
5. "Green Synthesis of Copper Nanoparticles Using *Coffee arabica*: Larvicidal and Biochemical Study. Journal of Bioscience and Applied Research, 2023, Vol.9, No. 4, P.199-211. <http://doi.org/10.21608/jbaar.2023.326117>
6. " *Coffee arabica*-derived copper nanoparticles: A potent larvicidal agent against *Aedes aegypti* mosquitoes" J Adv Biotechnol Exp Ther. 2024 May; 7(2): 314-327 eISSN: 2616-4760, <https://doi.org/10.5455/jabet.2024.d26>

### E. Papers at national and international scientific seminars and conferences.

1. "Biological and Biochemical Studies of *Biomphalaria arabica* Snails Exposed to Extract *Coffea arabica* Plant, The 5<sup>th</sup> International Conference on Science, 27 – 28 May 2022, UNHAS, Makassar, Indonesia.
2. "Histopathological and larvicidal study of copper nanoparticles synthesized using *Coffea arabica* extract against the dengue vector *Aedes aegypti* mosquito. 4th ICChSE International Conference on Chemistry and Science Education, 12 - 13 August, 2023 Universitas Negeri Padang, Indonesia.
3. "A Review on biological Synthesis of Nanoparticles: medical and agricultural Applications, The 4<sup>th</sup> International Conference on Science 21-23 August, 2023, Albyadaa University, Albyadaa, Yemen.